Solifenacin Succinate Versus Tolterodine 4mg Once Daily

Study Overview
=================
Brief Summary
-----------------
Prospective, double-blind, double-dummy, 2-arm, parallel-group, design. Flexible dose regimen for solifenacin succinate, fixed dose treatment regimen for tolterodine. Assessment of OAB symptoms by patient diaries.

Official Title
-----------------
Solifenacin in a Flexible Dose Regimen With Tolterodine as an Active Comparator in a Double-blind, Double-dummy, Randomised Overactive Bladder Symptom Trial

Conditions
-----------------
Urinary Bladder, Overactive

Intervention / Treatment
-----------------
* Drug: Solifenacin succinate
* Drug: Tolterodine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: At study entry: Patient is willing and able to complete the micturition diary correctly Symptoms of overactive bladder (including urinary frequency, urgency or urge incontinence) for >= 3 months At randomization: Patient must experience frequency of micturition on average >= 8 times per 24 hour period during the 3 day micturition diary period Patient must experience at least one of the following symptoms during the 3 day micturition diary period: At least 3 episodes of urinary incontinence or, Patients must exhibit urgency at least 3 times Exclusion Criteria: At study entry: Pregnant women or women who intend to become pregnant during the study or women of childbearing potential who are sexually active and practising an unreliable method of birth control or will be lactating during the study. Reliable contraceptive methods are intra-uterine devices, contraceptive pills of combination type, hormonal implants and injectable contraceptives Clinically significant outflow obstruction (at the discretion of the investigator) Significant post void residual volume (PVR>200ml) Significant stress incontinence or mixed stress/urge incontinence where stress is the predominant factor as determined by the investigator Patient with a neurological cause for abnormal detrusor activity Evidence of a symptomatic urinary tract infection, chronic inflammation such as interstitial cystitis, bladder stones, previous pelvic radiation therapy or previous or current malignant disease of the pelvic organs Uncontrolled narrow angle glaucoma, urinary or gastric retention or any other medical condition which in the opinion of the investigator makes the use of anticholinergics contra-indicated Non drug treatment including electrostimulation therapy or start of a bladder training program during the 2 weeks prior to entry into, or during the study Use of drugs intended to treat urinary incontinence Diabetic neuropathy Known or suspected hypersensitivity to solifenacin, tolterodine, other anticholinergics or lactose Any clinically significant condition, which in the opinion of the investigator makes the patient unsuitable for the trial Participation in any clinical trial within 30 (90 in the UK) days prior to randomisation Employees of the Yamanouchi Group, third parties associated with the study, or the study site At randomization: Patient who did not complete the micturition diary according to the instructions Total daily urine volume > 3000 ml as verified in the micturition diary

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: I<br>Solifenacin succinate 5/10mg | Drug: Solifenacin succinate<br>* oral<br>* Other names: Vesicare;|
| Experimental: II<br>Tolterodine 4mg | Drug: Tolterodine<br>* Oral<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change from baseline in mean number of micturitions per 24 hours |  | Weeks 4, 8 and 12 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change from baseline in mean urgency frequency per 24 hours |  | Weeks 4, 8 and 12 | 
| Change from baseline in mean number of incontinence and urge incontinence episodes per 24 hours |  | Weeks 4, 8 and 12 | 
| Change from baseline in mean volume voided per micturition |  | Weeks 4, 8 and 12 | 
| Change from baseline in number of pads used |  | Weeks 4, 8 and 12 | 
| Change from baseline in mean nocturia episodes per 24 hours |  | Weeks 4, 8 and 12 | 
| Percentage of patients requiring an increase in the dose of the study medication |  | Weeks 4, 8 and 12 | 
| Change from baseline in patient perception of bladder condition |  | Weeks 4, 8 and 12 | 
| Patient assessment of treatment benefit |  | Weeks 4, 8 and 12 | 
| Physician assessment of treatment benefit |  | Weeks 4, 8 and 12 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Overactive Bladder